Cargando…
Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe
INTRODUCTION: Lurasidone is a second-generation antipsychotic shown to have a lower risk of weight gain and a lower incidence of metabolic adverse events compared with some medications in the same class. OBJECTIVES: To describe treatment patterns, clinical outcomes and adverse drug reactions (ADRs)...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566357/ http://dx.doi.org/10.1192/j.eurpsy.2022.537 |